Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment

References

• 2022 GINA Report. Global Strategy for Asthma Management and Prevention Update 2022 Avaliable from: https://ginasthma.org/gina-reports/.
   Google Scholar
• Liebhart J, Dobek R, Małolepszy J, et al. The prevalence of allergic diseases in Poland-the results of the PMSEAD study in relation to gender differences. Adv Clin Exp Med. 2014;23(5):757–762. doi: 10.17219/acem/37238.
   PubMed Web of Science ®Google Scholar
• Chronic respiratory disease collaborators: global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5:691–706.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi: 10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest. 2020;157(3):516–528. doi: 10.1016/j.chest.2019.10.009.
   PubMed Web of Science ®Google Scholar
• Huang J, Pansare M. New treatments of asthma. Pediatr Clin North Am. 2019;66(5):925–939. doi: 10.1016/j.pcl.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Kardas G, Panek M, Kuna P, et al. Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives. Front Immunol. 2022;13:983852. doi: 10.3389/fimmu.2022.983852.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. doi: 10.1038/ni.3049.
   PubMed Web of Science ®Google Scholar
• Akar-Ghibril N, Casale T, Custovic A, et al. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–440. doi: 10.1016/j.jaip.2019.11.008.
   PubMed Web of Science ®Google Scholar
• Kardas G, Kuna P, Panek M. Biological therapies of severe asthma and their possible effects on airway remodeling. Front Immunol. 2020;11(11):1134. doi: 10.3389/fimmu.2020.01134.
   PubMedGoogle Scholar
• Yenigun A, Sezen S, Calim OF, et al. Evaluation of the eosinophil-to-lymphocytes ratio in pediatric patients with allergic rhinitis. Am J Rhinol Allergy. 2016;30(2):21–25.
   Web of Science ®Google Scholar
• Kant A, Terzioğlu K. Association of severity of allergic rhinitis with neutrophil-to-lymphocyte, eosinophil-to-neutrophil, and eosinophil-to-lymphocyte ratios in adults. Allergol Immunopathol. 2021;49(5):94–99. doi: 10.15586/aei.v49i5.204.
   PubMed Web of Science ®Google Scholar
• Mochimaru T, Ueda S, Suzuki Y, et al. Neutrophil-to-lymphocyte ratio as a novel independent predictor of severe exacerbation in patients with asthma. Ann Allergy Asthma Immunol. 2018;122(3):337–339.e1. doi: 10.1016/j.anai.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Gungen AC, Aydemir Y. The correlation between asthma disease and neutrophil to lymphocyte ratio. Res J Allergy Immunol. 2017;1:1–4.
   Google Scholar
• Shi G, Zhao JW, Ming L. Clinical significance of peripheral blood neutrophil-lymphocyte ratio and platelet- lymphocyte ratio in patients with asthma. Nan Fang Yi Ke Da Xue Xue Bao. 2017; 37(1):84–88.
   PubMedGoogle Scholar
• Zhang XY, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44(9):1137–1145. doi: 10.1111/cea.12345.
   PubMed Web of Science ®Google Scholar
• Özgen H, Tepetam FM, Bulut İ, et al. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma. Tuberk Toraks. 2021;69(1):39–48. doi: 10.5578/tt.20219905.
   PubMed Web of Science ®Google Scholar
• Huang WJ, Huang GT, Zhan QM, et al. The neutrophil to lymphocyte ratio as a novel predictor of asthma and its exacerbation: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24(22):11719–11728.
   PubMed Web of Science ®Google Scholar
• Branicka O, Rogala B, Glück J. Eosinophil/neutrophil/platelet-to-lymphocyte ratios in various types of immediate hypersensitivity to NSAIDs: a preliminary study. Int Arch Allergy Immunol. 2020;181(10):774–782. doi: 10.1159/000509116.
   PubMed Web of Science ®Google Scholar
• Brescia G, Pedruzzi B, Barion U, et al. Are neutrophil-, eosinophil-, and basophil- to- lymphocyte ratios useful markers for pinpointing patients at higher risk of recurrent sinonasal polyps? Am J Otolaryngol. 2016;37(4):339–345. doi: 10.1016/j.amjoto.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Kara A, Guven M, Yilmaz MS, et al. Are neutrophil, platelet and eosinophil-to-lymphocyte ratio and red blood cell distribution width can be used for nasal polyposis? Eur Arch Otorhinolaryngol. 2018;275(2):409–413. doi: 10.1007/s00405-017-4821-3.
   PubMed Web of Science ®Google Scholar
• Tecimer SH, Kasapoglu F, Demir UL, et al. Correlation between clinical findings and eosinophil/neutrophil ratio in patients with nasal polyps. Eur Arch Otorhinolaryngol. 2015;272(4):915–921. doi: 10.1007/s00405-014-3174-4.
   PubMed Web of Science ®Google Scholar
• Brescia G, Barion U, Zanotti C, et al. Pre- and postoperative blood neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios in patients with sinonasal polyps: a preliminary investigation. Allergy Asthma Proc. 2017;38(5):64–69. doi: 10.2500/aap.2017.38.4068.
   PubMed Web of Science ®Google Scholar
• Programy Lekowe. [26 February 2018] Available from: http://www.archiwum.mz.gov.pl/leki/refundacja/programy-lekowe/.
   Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi: 10.1034/j.1399-3003.1999.14d29.x.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115(5):1265–1270. doi: 10.1378/chest.115.5.1265.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164.e1. doi: 10.1016/j.jaip.2018.04.043.
   PubMed Web of Science ®Google Scholar
• Kavati A, Zhdanava M, Ortiz B, et al. Retrospective study on the association of biomarkers with real-world outcomes of omalizumab-treated patients with allergic asthma. Clin Ther. 2019;41(10):1956–1971. doi: 10.1016/j.clinthera.2019.07.021.
   PubMed Web of Science ®Google Scholar
• Kallieri M, Papaioannou AI, Papathanasiou E, et al. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Postgrad Med. 2017;129(6):598–604. doi: 10.1080/00325481.2017.1321945.
   PubMed Web of Science ®Google Scholar
• Kucharczyk A, Więsik-Szewczyk E, Poznańska A, et al. Clinical determinants of successful omalizumab therapy in severe allergic asthma patients: 4-year-long, real-life observation. J Asthma Allergy. 2020;13:659–668. doi: 10.2147/JAA.S282203.
   PubMed Web of Science ®Google Scholar